- Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer - updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort CShen, L.; Liu, D.; Li, N.; Guo, W.; Liu, T.; Li, H.; Li, J.; Zhao, F.; Sun, M.; Bai, Y.; Deng, Y.; Zhuang, Z.; Fan, Q.; Han, L.; Xia, S.; Zhu, X.; Qi, C.; Xu, L.; Qian, X.; Germa, C.
- First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumorsWang, Yakun; Gong, Jifang; Lin, Rongbo; Zhao, Shen; Wang, Jufeng; Wang, Qianli; Zhang, Yanqiao; Su, Dan; Zhang, Jingdong; Dong, Qian; Lin, Ling; Tian, Wen; Chen, Ying; Yang, Yang; Zhang, Xueyuan; Wan, Xuechao; Gao, Jinfeng; An, Na; Jansen, Valerie Malyvanh; Shen, LinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)Shen, Lin; Liu, Dan; Li, Ning; Guo, Weijian; Liu, Tianshu; Li, Hongli; Li, Jiayi; Bai, Yuxian; Deng, Yanhong; Zhuang, Zhi-xiang; Sun, Meili; Fan, Qingxia; Zhao, Fuyou; Han, Liang; Xia, Zhenzhong; Wang, Jianming; Qi, Charlie; Xu, Li; Qian, Xueming; Germa, CarolineAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.
7阅读
